Kezar Life Sciences Inc [KZR] stock is trading at $0.61, up 5.05%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The KZR shares have gain 7.51% over the last week, with a monthly amount drifted -6.25%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Kezar Life Sciences Inc [NASDAQ: KZR] stock has seen the most recent analyst activity on August 11, 2023, when Wells Fargo downgraded its rating to a Equal Weight but kept the price target unchanged to $4 for it. Previously, William Blair downgraded its rating to Mkt Perform on March 16, 2023. On December 08, 2021, Wells Fargo initiated with a Overweight rating and assigned a price target of $19 on the stock. William Blair started tracking the stock assigning a Outperform rating. Wells Fargo initiated its recommendation with a Outperform and recommended $30 as its price target on July 16, 2018.
Kezar Life Sciences Inc [KZR] stock has fluctuated between $0.54 and $1.68 over the past year. Currently, Wall Street analysts expect the stock to reach $17.5 within the next 12 months. Kezar Life Sciences Inc [NASDAQ: KZR] shares were valued at $0.61 at the most recent close of the market. An investor can expect a potential return of 2768.85% based on the average KZR price forecast.
Analyzing the KZR fundamentals
Gross Profit Margin for this corporation currently stands at 0.31% with Operating Profit Margin at -63.32%, Pretax Profit Margin comes in at -62.7%, and Net Profit Margin reading is -62.7%. To continue investigating profitability, this company’s Return on Assets is posted at -0.55, Equity is -0.55 and Total Capital is -0.61. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.5753 points at the first support level, and at 0.5412 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.6318, and for the 2nd resistance point, it is at 0.6542.
Ratios To Look Out For
For context, Kezar Life Sciences Inc’s Current Ratio is 9.58. In addition, the Quick Ratio stands at 9.58 and the Cash Ratio stands at 1.62. Considering the valuation of this stock, the price to sales ratio is 6.34, the price to book ratio is 0.29.
Transactions by insiders
Recent insider trading involved Schiller Mark C., Chief Legal Officer, that happened on Jul 02 ’24 when 6688.0 shares were sold.
